PFA
AZN icon

Pathway Financial Advisers’s AstraZeneca AZN Stock Holding History

Pathway Financial Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-143
Closed -$21.9K – 179
2025
Q3 		$21.9K Buy
+143
New +$21.6K 0.01% 295
2025
Q1 		– Sell
-142
Closed -$18.6K – 179
2024
Q4 		$18.6K Hold
142
– – 0.01% 313
2024
Q3 		$22.1K Hold
142
– – 0.01% 244
2024
Q2 		$22.1K Sell
142
-74
-34% -$11.1K 0.01% 278
2024
Q1 		$29.3K Buy
216
+74
+52% +$9.8K 0.01% 270
2023
Q4 		$19.1K Sell
142
-122
-46% -$15.9K 0.01% 300
2023
Q3 		$35.8K Buy
+264
New +$36.1K 0.01% 245
2023
Q1 		$36.5K Buy
263
+1
+0.4% +$135 0.01% 253
2022
Q4 		$35.5K Buy
+262
New +$32.9K 0.01% 272

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pathway Financial Advisers's AZN Position: Q4 2025 in Review

Pathway Financial Advisers sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 143 shares — an estimated $21.9K sold.

Pathway Financial Advisers first reported a position in AZN in Q4 2022 and held it in 9 quarters. The position peaked at $36.5K in Q1 2023. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Pathway Financial Advisers reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Pathway Financial Advisers sold 143 AstraZeneca shares in Q4 2025, an estimated $21.9K.
  • Pathway Financial Advisers first reported a position in AstraZeneca in Q4 2022 and held it in 9 quarters.
  • Pathway Financial Advisers's AstraZeneca position peaked at $36.5K in Q1 2023.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Pathway Financial Advisers's 13F filing for Q4 2025, filed 6 Feb 2026.